This document is an excerpt from the EUR-Lex website
Document 62022TN0174
Case T-174/22: Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTREV)
Case T-174/22: Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTREV)
Case T-174/22: Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTREV)
OJ C 207, 23.5.2022, p. 52–53
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
OJ C 207, 23.5.2022, p. 37–37
(GA)
|
23.5.2022 |
EN |
Official Journal of the European Union |
C 207/52 |
Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTREV)
(Case T-174/22)
(2022/C 207/69)
Language in which the application was lodged: English
Parties
Applicant: Novartis AG (Basel, Switzerland) (represented by: A. Nordemann-Schiffel, lawyer)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: AstraZeneca AB (Södertälje, Sweden)
Details of the proceedings before EUIPO
Applicant of the trade mark at issue: Other party to the proceedings before the Board of Appeal
Trade mark at issue: Application for European Union word mark BREZTREV — Application for registration No 18 088 373
Procedure before EUIPO: Opposition proceedings
Contested decision: Decision of the Second Board of Appeal of EUIPO of 21 January 2022 in Case R 738/2021-2
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision; |
|
— |
order EUIPO to pay the costs. |
Plea in law
|
— |
Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |